| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Chang Pengyu | Q90682832 |
| P2093 | author name string | Tingting Liang | |
| Weihua Tong | |||
| Siyang Ma | |||
| P2860 | cites work | Cancer classification using the Immunoscore: a worldwide task force | Q21245495 |
| Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation | Q26744490 | ||
| The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis | Q26748194 | ||
| Radiotherapy and the tumor stroma: the importance of dose and fractionation | Q27022685 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| T cell exclusion, immune privilege, and the tumor microenvironment | Q28259872 | ||
| Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 | ||
| Exploring the role of cancer stem cells in radioresistance | Q28282037 | ||
| Molecular basis of T cell inactivation by CTLA-4 | Q28291723 | ||
| Immunogenic cell death in cancer therapy | Q29620118 | ||
| IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours | Q33786422 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy | Q34442153 | ||
| Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy | Q34705000 | ||
| Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer | Q35061159 | ||
| Molecular interactions mediating T cell antigen recognition | Q35077424 | ||
| A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer | Q35835138 | ||
| Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis | Q36112303 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. | Q36348179 | ||
| A meta-analysis of CXCL12 expression for cancer prognosis | Q36378583 | ||
| Immunological off-target effects of standard treatments in gastrointestinal cancers | Q37404086 | ||
| The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target | Q38161542 | ||
| Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells | Q38209441 | ||
| Radiobiological basis of SBRT and SRS. | Q38226118 | ||
| The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence | Q38536374 | ||
| Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications | Q38919760 | ||
| Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer | Q39066439 | ||
| Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. | Q39535140 | ||
| Immunogenic death of colon cancer cells treated with oxaliplatin | Q39780621 | ||
| Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells | Q39884086 | ||
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. | Q40248504 | ||
| Satellite DNA: An Evolving Topic | Q41673553 | ||
| Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer. | Q44080157 | ||
| A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients | Q44412713 | ||
| An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. | Q46017879 | ||
| CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients | Q46228932 | ||
| Association Between Natural Killer Cell Activity and Colorectal Cancer in High-Risk Subjects Undergoing Colonoscopy | Q47342903 | ||
| Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer | Q48127437 | ||
| Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. | Q48507831 | ||
| The significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. | Q49719408 | ||
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Q49887005 | ||
| Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors | Q50044559 | ||
| Targeting the RAS-dependent chemoresistance: The Warburg connection | Q50060608 | ||
| Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer | Q50064995 | ||
| Genetic mechanisms of immune evasion in colorectal cancer | Q50420634 | ||
| TNM staging in colorectal cancer: T is for T cell and M is for memory. | Q51023195 | ||
| Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. | Q51590802 | ||
| Cancer immunotherapy using checkpoint blockade. | Q52641912 | ||
| Results and challenges of immune checkpoint inhibitors in colorectal cancer. | Q52689522 | ||
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. | Q52861120 | ||
| Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. | Q53081522 | ||
| Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. | Q54114270 | ||
| Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. | Q54440237 | ||
| The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. | Q54942438 | ||
| Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. | Q55046482 | ||
| Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Q55190117 | ||
| Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. | Q55264112 | ||
| Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. | Q55491553 | ||
| Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer | Q56895579 | ||
| Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer | Q56932490 | ||
| A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization | Q57025289 | ||
| Engaging the vascular component of the tumor response | Q57359877 | ||
| Time to abandon single-site irradiation for inducing abscopal effects | Q58608193 | ||
| Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response | Q59070397 | ||
| Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion | Q62556943 | ||
| Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) | Q64245602 | ||
| Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity | Q83135484 | ||
| CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer | Q87354117 | ||
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q88932345 | ||
| Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing | Q89243487 | ||
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial | Q90023691 | ||
| The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients | Q90407409 | ||
| Cancer Stem Cells: The Architects of the Tumor Ecosystem | Q90884451 | ||
| Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe? | Q91172135 | ||
| Adaptive mutability of colorectal cancers in response to targeted therapies | Q91172844 | ||
| CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer | Q91195832 | ||
| Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial | Q91792483 | ||
| Clonal replacement of tumor-specific T cells following PD-1 blockade | Q92267499 | ||
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data | Q92709040 | ||
| Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers | Q93196424 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal neoplasm | Q58833976 | ||
| P304 | page(s) | 1773205 | |
| P577 | publication date | 2020-06-03 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer | |
| P478 | volume | 9 |
Search more.